Novartis and Eli Lilly are opposing a Kerala High Court petition seeking to lower the prices of breast cancer drugs Ribociclib and Abemaciclib. Court filings highlight a wide gap between global revenues and Indian retail costs, raising questions about pricing strategies. This case poses a potential regulatory risk for multinational pharmaceutical companies regarding price controls in India.
Multinational pharmaceutical giants Novartis and Eli Lilly are currently contesting a legal petition in the Kerala High Court. The petition seeks government intervention to mandate price reductions for life-saving breast cancer medications, specifically Novartis's ribociclib and Eli Lilly's abemaciclib. The ongoing legal battle is placing the spotlight on how multinational companies price patented drugs in the Indian market compared to their global performance.
Global Revenue vs. Indian Market Impact
Financial data presented to the court reveals a sharp contrast between the global success of these drugs and their footprint in India. For Novartis, ribociclib generated approximately $12.7 billion in global revenue between 2020 and 2025, while India contributed $55.7 million, accounting for roughly 0.4% of the total. Similarly, Eli Lilly’s abemaciclib reported $19.6 billion in global revenue against $31.5 million in India. Despite the relatively small contribution from the Indian market, the pricing remains a point of contention for local patients and regulators.
Production Costs and R&D Defense
The core of the dispute centers on the transparency of pricing. While the companies argue that their high retail prices are necessary to recover substantial research and development costs, petitioners have challenged this narrative. Data submitted to the court suggests a significant gap between manufacturing and retail. For instance, estimates indicate that the monthly cost to produce a ribociclib regimen could range between Rs 5,100 and Rs 7,750. In comparison, the drug is currently retailed by Novartis for approximately Rs 78,400.
Industry-backed figures, such as the $2.6 billion estimate for total drug development costs, have been questioned by analysts who argue that such estimates may be inflated to justify premium pricing in emerging markets. The companies maintain that their patent protections are essential to sustain future innovation.
Implications for Investors
For investors monitoring the pharmaceutical sector, this case is significant because it highlights the regulatory and reputational risks of pricing strategies in India. The country’s National Pharmaceutical Pricing Authority (NPPA) regulates drug costs under the Drug Price Control Order (DPCO). Any legal or regulatory move that forces companies to lower prices could impact profit margins for MNC pharma firms operating in India.
Furthermore, India’s strong generic pharmaceutical sector has historically provided lower-cost alternatives once patents expire. If the court allows for stricter price controls or if the government decides to intervene, it could create a precedent for how patented drugs are priced in the country. Investors should monitor the court's upcoming hearings and any subsequent commentary from the government regarding the expansion of price controls on specialty oncology drugs, as these factors could influence the long-term profitability of MNC pharma portfolios in the region.